Generation Bio Appoints Dr. Richard Thompson to its Scientific Advisory Board
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 4, 2018--Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, today announced the appointment of Richard Thompson, BM BCh, DM, a world-renowned specialist in pediatric liver disease, to its Scientific Advisory Board.
“Richard is an accomplished physician-scientist who has built his career developing a deep understanding of the genetic basis of pediatric and adult liver disease,” said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. “We are delighted to welcome him to our Scientific Advisory Board and look forward to drawing on his experience as we build a portfolio of ceDNA-based genetic medicines for patients with liver diseases.”
Dr. Thompson is the Professor of Molecular Hepatology at King’s College London and honorary consultant pediatric hepatologist at King’s College Hospital, London. He specializes in pediatric liver disease and is particularly interested in genetic liver disease in both children and adults. Through worldwide collaborations, Richard’s lab continues to identify new causes of genetic liver disease. Richard served as the clinical lead for genomics and the 100,000 genome project at King’s College Hospital, and is the clinical lead for a diagnostic laboratory specializing in liver and gastrointestinal disease.
“Generation Bio is creating truly novel genetic medicines whose unique characteristics make early intervention possible and crucially, sustainable through the growth of the liver in childhood,” said Dr. Thompson. “I look forward to the opportunity to help the company to benefit patients with a broad range of liver diseases.”
About Generation Bio
Generation Bio is a biotechnology company developing a breakthrough class of genetic medicines to enable a new generation of people to live unaffected by inherited disease. The company’s therapies are based on its proprietary ceDNA technology, which delivers durable, high levels of gene expression and can be re-dosed to titrate to effect and to sustain impact over a lifetime. Generation Bio was founded and launched by Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.generationbio.com or follow @lifetimegenetx.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181004005024/en/
CONTACT: Ten Bridge Communications
Sarah Sutton, 518-932-3680
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL
SOURCE: Generation Bio
Copyright Business Wire 2018.
PUB: 10/04/2018 08:00 AM/DISC: 10/04/2018 08:01 AM